Trials / Completed
CompletedNCT01982747
A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703
A Phase I, Placebo-Controlled, Double-Blind, 2-Period Crossover Study to Assess Cardiac and General Safety and Pharmacokinetics of a Single Subcutaneous Dose of 60 mg MGN1703 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Mologen AG · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
MGN1703 is being developed for use in treating cancerous tumors effecting the colon, skin, kidneys and lungs. The dosage form of MGN1703 under investigation is an injection. The goal of this study is to evaluate the effects of MGN1703 on the electrical activity of the heart in healthy subjects and to look at general safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MGN-Placebo | |
| DRUG | Placebo-MGN |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2013-11-13
- Last updated
- 2014-05-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01982747. Inclusion in this directory is not an endorsement.